[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Anderson SE, Keohan ML, D'Adamo DR, Maki RG: A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma; 2006;2006:15947
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas.
  • Introduction. The role of vinorelbine in specific soft tissue sarcoma subtypes is unclear.
  • We present retrospective single institution experience with single-agent vinorelbine in subjects with metastatic soft tissue malignancies.
  • Doxorubicin had been administered previously to 53 subjects (91%), and the median number of lines of previous chemotherapy was 3 (range 0-7).
  • The overall response rate was 6% (3 patients: 1 angiosarcoma, 1 epithelioid sarcoma, and 1 embryonal rhabdomyosarcoma).
  • Median time to progression was 1.8 months (95% confidence intervals 1.5-2.1 months, Kaplan-Meier estimate).
  • Conclusion. Vinorelbine demonstrates limited activity in a heavily pretreated group of soft-tissue sarcoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3263-8 [12115359.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Semin Surg Oncol. 1988;4(1):53-8 [3281212.001]
  • [Cites] Cancer Treat Rep. 1976 Feb;60(2):199-203 [769974.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1550-7 [10735904.001]
  • (PMID = 17496991.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA047179
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC1698137
  •  go-up   go-down


2. Garg V, Zhang W, Gidwani P, Kim M, Kolb EA: Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clin Cancer Res; 2007 Sep 15;13(18 Pt 1):5446-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
  • RESULTS: The IC(50) in Ewing's sarcoma, rhabdomyosarcoma, osteosarcoma, and synovial sarcoma lines ranged from 0.002 micro to 0.32 micromol/L.
  • In the SK-ES1 and RH30 cell lines, tasidotin induced a G(2)-M arrest that persisted for 48 h after the drug was washed from the cells.
  • In vitro, more than half the cells were in the early or late phase of apoptosis 48 h after treatment with tasidotin.
  • A complete response was observed in 2 synovial sarcoma lines, 1 osteosarcoma line, 1 rhabdomyosarcoma line, and 1 Ewing's sarcoma line.
  • A partial response was observed in 1 rhabdomyosarcoma and 1 Ewing's sarcoma.
  • [MeSH-major] Bone Neoplasms / drug therapy. Oligopeptides / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Animals. Apoptosis. Cell Cycle / drug effects. Cell Line, Tumor. Cytoprotection. Drug Evaluation, Preclinical. Humans. Inhibitory Concentration 50. Mice. Mice, SCID. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / pathology. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / pathology. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / pathology. Xenograft Model Antitumor Assays


3. Frühwald MC, Rickert CH, O'Dorisio MS, Madsen M, Warmuth-Metz M, Khanna G, Paulus W, Kühl J, Jürgens H, Schneider P, Müller HL: Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging. Clin Cancer Res; 2004 May 1;10(9):2997-3006
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Although gliomas predominate among central nervous system (CNS) neoplasms in adulthood, embryonal tumors are the most common malignant brain tumors in children.
  • Despite novel treatment approaches, including improved radiotherapy and high-dose chemotherapy, survival rates remain unsatisfactory.
  • The timely diagnosis of residual or recurrent embryonal CNS tumors and thus the earliest possible time point for intervention is often hampered by inaccuracies of conventional imaging techniques.
  • Here, we evaluated somatostatin receptor type 2 (sst(2)) expression using an antibody in an array of CNS tumors of childhood.
  • RESULTS: Abundant expression of somatostatin receptor type 2 in stPNET, a ME, and ependymomas warranted in vivo imaging of 7 stPNET, 1 rhabdomyosarcoma, 3 ependymomas, 1 ME, and 1 glioblastoma.
  • Although SRI was positive in 6/7 stPNET, 1 rhabdomyosarcoma, and 1 ME, none of the ependymomas nor the glioblastoma could be imaged using SRI.
  • In selected cases SRI was more sensitive in the detection of relapse than conventional imaging by magnetic resonance imaging and computed tomography.
  • CONCLUSIONS: SRI should be considered in the evaluation of residual or recurrent embryonal CNS tumors, especially stPNET.
  • The strengths of SRI lie in the differentiation of reactive tissue changes versus residual or recurrent tumor, the detection of small lesions, and possibly in the distinction of stPNET from gliomas.
  • [MeSH-minor] Central Nervous System Neoplasms / metabolism. Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / radionuclide imaging. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Tomography, Emission-Computed, Single-Photon / methods

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumors, childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15131035.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2
  •  go-up   go-down


Advertisement
4. Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A: Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer; 2005 Aug 15;104(4):856-63
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median doses of 50-55 grays (Gy) in 25-27 fractions were delivered to the whole breast over a period of 5-5.5 weeks (2 Gy/day, 5 weekly fractions) followed, when indicated, by a 16-26-Gy boost to the tumor or tumor bed.
  • Treatment of radiation-induced sarcomas (RIS) consisted mostly of radical surgery and chemotherapy.
  • RESULTS: Overall, 35 patients developed sarcomas.
  • Histologic evaluation identified 13 angiosarcomas, 3 osteosarcomas, 5 undifferentiated sarcomas, 1 malignant fibrous histiocytoma, 2 leiomyosarcomas, 1 fibrosarcoma, 1 rhabdomyosarcoma, and 1 myosarcoma.
  • However, it showed that the risk increased with time.
  • Therefore, careful, long-term follow-up of patients treated with radiotherapy is needed for early detection and efficacious treatment of these malignancies.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Breast / surgery. Female. Humans. Incidence. Middle Aged. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / therapy. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981282.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Davidson A, Dick G, Pritchard-Jones K, Pinkerton R: EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation. Eur J Cancer; 2002 Dec;38(18):2422-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation.
  • Tumour types were neuroblastoma 3, Ewing's sarcoma 2, rhabdomyosarcoma 5, osteosarcoma 3, desmoplastic small round cell tumour 1, nephroblastoma 1, T-acute lymphoblastic leukaemia (ALL) 1.
  • All had progressed or relapsed following at least two of the drug types included in EVE.
  • Partial responses (PR) were observed in 2 patients (1 rhabdomyosarcoma, 1 Ewing's sarcoma).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclosporine / administration & dosage. Cyclosporine / adverse effects. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gastrointestinal Diseases / chemically induced. Heart Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Kidney Diseases / chemically induced. Male. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2002 Dec;38(18):2337-40 [12460776.001]
  • (PMID = 12460787.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


6. Lin HF, Lui CC, Hsu HC, Lin SA: Orbital exenteration for secondary orbital tumors: a series of seven cases. Chang Gung Med J; 2002 Sep;25(9):599-605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It entails the removal of the eyeball together with its extraocular muscles and other soft tissues.
  • Primary lesions, histopathological examination results, treatments, and recurrences are discussed.
  • Two patients underwent total exenteration without socket augmentation; 4 patients underwent exenteration/ subtotal exenteration with immediate facial reconstruction, and 1 with delayed facial reconstruction.
  • RESULTS: Classification of the 7 patients showed that 2 had basal cell carcinoma of the skin, 2 had squamous cell carcinoma of the conjunctiva, 1 had squamous cell carcinoma of the paranasal sinus, 1 had rhabdomyosarcoma of the paranasal sinus, and 1 had intracranial meningioma.
  • Radiotherapy was performed in 6 of the patients and chemotherapy in 2.
  • CONCLUSION: Secondary orbital tumors involved the orbit from adjacent tissues: paranasal sinuses, nasopharynx, lacrimal sac, conjunctiva, eyelid, intraocular tissue, and intracranial tissues.
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Rhabdomyosarcoma / surgery. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479621.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


7. Abellar RG, Pepperell JR, Greco D, Gundogan F, Kostadinov S, Schwartz J, Tantravahi U, De Paepe ME: Effects of chemotherapy during pregnancy on the placenta. Pediatr Dev Pathol; 2009 Jan-Feb;12(1):35-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of chemotherapy during pregnancy on the placenta.
  • Whereas the effects of chemotherapy during pregnancy for mother and fetus are well described, its effects on the placenta remain largely undetermined.
  • We performed a retrospective clinicopathologic analysis of the placenta following chemotherapy.
  • Charts were reviewed for type of malignancy, type and timing of chemotherapy, and fetal and pregnancy outcome.
  • Patients (n = 13) underwent chemotherapy during pregnancy for carcinoma of breast (3), ovary (2), cervix (2), salivary gland (1), lymphoma/leukemia (4), or rhabdomyosarcoma (1).
  • Eleven patients were treated with DNA-active cytotoxic agents during the 2nd and/or 3rd trimesters; their placentas showed nonspecific findings, including villous hypermaturity, distal villous hypoplasia, villous edema, and excessive extravillous trophoblast, and 4/11 (36%) were small-for-age.
  • In one case (rhabdomyosarcoma), the mother was exposed to cytotoxic agents throughout the entire pregnancy.
  • Our findings suggest that chemotherapy during the 1st trimester induces excessive polyploidization of the chorion laeve trophoblast, likely representing an adaptive response to intraamniotic toxins.
  • However, without appropriate controls (untreated patients with equivalent malignancies), the specific effects of chemotherapy in this group are difficult to assess.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Placenta / drug effects. Placenta / pathology. Pregnancy Complications, Neoplastic / drug therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462010.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM: Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol; 2008 Nov-Dec;26(6):595-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Two patients presented with clinical stage I disease in which malignant transformation occurred within the primary testis tumor (rhabdomyosarcoma in 1 and adenocarcinoma in 1).
  • Of the remaining 7 patients, the clinical stages were IIA (N = 1), IIB (N = 3), and III (N = 3), and all were treated with chemotherapy followed by RPLND.
  • The MTT histology of these RPLND specimens consisted of adenocarcinoma (N = 3), rhabdomyosarcoma (N = 2), angiosarcoma (N = 1), and astrocytoma (N = 1).
  • Following preoperative chemotherapy, a significant radiologic response (defined as more than a 25% reduction in maximum tumor circumferential diameter) was demonstrated in 1 patient, and normalization of serum tumor markers was demonstrated in 6.
  • CONCLUSIONS: In our experience, MTT is significantly resistant to current chemotherapeutic regimens, as demonstrated by its poor radiologic response to treatment.
  • Alternative therapeutic strategies targeted to MTT are thus needed.
  • [MeSH-major] Teratoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Drug Resistance, Neoplasm. Humans. Lymph Node Excision. Male. Neoplasm Staging. Retroperitoneal Space

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2781-8 [15837993.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1998 Jun;89(6):622-6 [9666691.001]
  • [Cites] Semin Urol Oncol. 1998 May;16(2):65-71 [9649229.001]
  • [Cites] J Urol. 1998 Mar;159(3):859-63 [9474169.001]
  • [Cites] Scand J Urol Nephrol. 2003;37(2):177-8 [12745729.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):860-3 [2990657.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4285-91 [14645417.001]
  • [Cites] J Urol. 1998 Jan;159(1):133-8 [9400455.001]
  • [CommentIn] Urol Oncol. 2009 Mar-Apr;27(2):218; author reply 218-9 [19285238.001]
  • (PMID = 18367105.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS610854; NLM/ PMC4121060
  •  go-up   go-down


9. Rasmussen A, Kvist N, Kirkegaard P, Rechnitzer C: [Surgical treatment of children with hepatic tumours]. Ugeskr Laeger; 2008 Apr 14;170(16):1366-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of children with hepatic tumours].
  • [Transliterated title] Kirurgisk behandling af levertumorer hos børn.
  • INTRODUCTION: In this paper we review the results of surgical treatment of children with hepatic tumours.
  • 26 patients had hepatoblastoma, 3 had hepatocellular carcinoma, 2 had rhabdomyosarcoma, 1 had a mesenchymal tumour, and 1 had a giant haemangioma.
  • RESULTS: Because of the number of patients, we only analyzed the results of the treatment in the hepatoblastoma group.
  • There was no difference in survival dependent on the type of resection, and there was no impact of the extension of tumour growth at the time of diagnosis.
  • CONCLUSION: The combination of neoadjuvant chemotherapy followed by liver resection or liver transplantation is the treatment of choice in all children with hepatoblastoma.
  • Since 2000, very effective chemotherapy has downstaged all referred patients, so subsequent liver resection have been possible.
  • [MeSH-minor] Child. Hepatectomy. Humans. Liver Transplantation. Neoadjuvant Therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433603.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


10. Langevin AM, Bernstein M, Kuhn JG, Blaney SM, Ivy P, Sun J, Chen Z, Adamson PC, Children's Oncology Group: A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2008 Mar;50(3):577-80
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Rebeccamycin Analogue (NSC #655649), a chemically synthesized glycosyl-dichloro-indolocarbazole derivative of rebeccamycin with topoisomerase inhibiting activity, has in vitro activity against pediatric tumor cell lines and tumor specimens including rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma and medulloblastoma.
  • PROCEDURE: The primary objective of this trial was to determine the response rate to Rebeccamycin analogue NSC #655649 in children with refractory solid and CNS tumors.
  • Rebeccamycin analogue, 650 mg/m(2), was administered every 21 days, and could be escalated to 780 mg/m(2) in subsequent cycles to achieve a maximum plasma drug concentration >5 microg/ml.
  • Of 126 evaluable patients for response, only 4 patients had an objective response: 3 patients with rhabdomyosarcoma (1 CR and 2 PR) and 1 patient with neuroblastoma (1 PR).
  • CONCLUSIONS: The 15% response rate to Rebeccamycin analogue observed in patients with rhabdomyosarcoma, while of interest, is associated with significant myelosuppression.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Diseases / chemically induced. Carbazoles. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug-Induced Liver Injury / etiology. Female. Glucosides. Humans. Infant. Infant, Newborn. Infusions, Intravenous. Male. Neoplasm Proteins / antagonists & inhibitors. Pancreatitis / chemically induced. Rhabdomyosarcoma / drug therapy. Salvage Therapy. Topoisomerase II Inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17610262.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / P30CA-54174
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibiotics, Antineoplastic; 0 / Carbazoles; 0 / Glucosides; 0 / Neoplasm Proteins; 0 / Topoisomerase II Inhibitors; A60X6MBU6G / becatecarin
  •  go-up   go-down


11. Blanchard DK, Reynolds CA, Grant CS, Donohue JH: Primary nonphylloides breast sarcomas. Am J Surg; 2003 Oct;186(4):359-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to examine the presentation, treatment, and prognosis of patients presenting with these neoplasms.
  • RESULTS: Of the 55 patients, 17 had breast-conserving therapy and 38 women had mastectomy.
  • The types of sarcoma included angiosarcoma (18), malignant fibrous histiocytoma (11), stromal sarcoma (8), liposarcoma (4), leiomyosarcoma (4), dermatofibrosarcoma protuberans (4), osteosarcoma (3), fibrosarcoma (2), and rhabdomyosarcoma (1).
  • Twenty-nine of 53 patients (55%) developed recurrent sarcoma, and 23 patients (43%) died of their disease.
  • Of 34 patients who did not receive adjuvant chemotherapy or radiation, 13 died of their disease (38%), as compared with 10 of 16 patients (63%) who did receive adjuvant therapy.
  • CONCLUSIONS: While primary nonphylloides breast sarcomas are rare tumors, their treatment and prognosis are poor.
  • Adjuvant chemotherapy and radiation did not improve survival in this report.
  • Surgical extirpation remains the only effective treatment.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14553850.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kebudi R, Ayan I, Görgün O, Ağaoğlu FY, Vural S, Darendeliler E: Brain metastasis in pediatric extracranial solid tumors: survey and literature review. J Neurooncol; 2005 Jan;71(1):43-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to investigate the incidence, treatment, prognosis of brain metastasis in extracranial pediatric malignant tumors in a single institution and to review the literature.
  • RESULTS: Sixteen (10 female, 6 male) of 1100 patients (1.45%) with extracranial solid tumors developed brain metastases.
  • The diagnosis was sarcomas in 12 patients: 5 osteosarcomas, 4 Ewing's sarcoma family tumors, 1 rhabdomyosarcoma, 1 clear cell sarcoma of the soft tissue, 1 alveolar soft part sarcoma.
  • Twelve (75%) developed brain metastasis during therapy or relapse at a median duration of 16 (1-70) months from initial diagnosis.
  • All patients had metastases to various sites, mostly lung, at the time the brain metastases were detected.
  • Treatment included surgery, followed by postoperative radiotherapy (RT) and chemotherapy (CT) in 1, S and RT in 1, S in 1, RT and CT in 6, RT in 1, CT in 1 and no treatment in 5.
  • All other patients died at a median time of 2 months (2 days-6 months) from the time of brain metastasis.
  • Although, the outcome for these patients is dismal in this series and in the literature; reports of long term survival in a few cases with Wilms' tumor, osteosarcoma and alveolar soft part sarcoma who had isolated brain metastasis, suggest that a subset of patients may benefit from therapy.
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Bone Neoplasms / epidemiology. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Child. Child, Preschool. Female. Humans. Infant. Lung Neoplasms / epidemiology. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Mediastinal Neoplasms / epidemiology. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Germ Cell and Embryonal / therapy. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Wilms Tumor / epidemiology. Wilms Tumor / secondary. Wilms Tumor / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Feb 1;61(3):593-601 [3276383.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2160-4 [6593114.001]
  • [Cites] Oncology. 1995 Mar-Apr;52(2):89-92 [7854781.001]
  • [Cites] Arch Neurol. 1988 Jul;45(7):741-4 [3390029.001]
  • [Cites] Neurosurg Rev. 1990;13(3):247-52 [1697937.001]
  • [Cites] Eur J Nucl Med. 1983;8(12 ):552-4 [6230234.001]
  • [Cites] Pediatr Neurol. 2002 Mar;26(3):219-21 [11955930.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Nov-Dec;16(6):545-9 [10599095.001]
  • [Cites] J Neurooncol. 1988;6(1):47-52 [3165112.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3656-60 [8490913.001]
  • [Cites] Cancer. 1982 Jun 1;49(11):2404-9 [7074552.001]
  • [Cites] J Pediatr. 1983 Oct;103(4):558-61 [6620015.001]
  • [Cites] Neurology. 1974 Oct;24(10):981-5 [4369837.001]
  • [Cites] J Korean Med Sci. 1997 Oct;12(5):473-6 [9364310.001]
  • [Cites] Indian J Cancer. 1997 Mar;34(1):26-9 [9491660.001]
  • [Cites] Lancet Oncol. 2002 Aug;3(8):498-507 [12147436.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):2023-9 [9806663.001]
  • [Cites] Med Pediatr Oncol. 2002 Jul;39(1):60-2 [12116085.001]
  • [Cites] Cancer. 1980 Jan 15;45(2):377-80 [6243247.001]
  • [Cites] Neurol Med Chir (Tokyo). 1994 Nov;34(11):754-8 [7533270.001]
  • [Cites] Neurology. 1998 Nov;51(5):1336-8 [9818856.001]
  • [Cites] Neurosurgery. 1979 Jul;5(1 Pt 1):44-8 [471204.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 3:iii4-10 [12821532.001]
  • [Cites] Cancer. 1979 Feb;43(2):707-10 [283879.001]
  • [Cites] Neurosurgery. 1994 Aug;35(2):185-90; discussion 190-1 [7969824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Aug;8(8):1441-6 [7141922.001]
  • [Cites] Jpn J Clin Oncol. 1999 May;29(5):245-7 [10379335.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):177-83 [12909231.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Sep-Oct;21(5):370-7 [10524449.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):403-10 [9010115.001]
  • [Cites] Acta Neuropathol. 1985;67(3-4):341-4 [4050350.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):149-55 [1734220.001]
  • [Cites] Surg Neurol. 1998 Apr;49(4):441-4 [9537665.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):699-702 [3838542.001]
  • [Cites] Pediatr Neurosurg. 1999 Jun;30(6):331-4 [10494060.001]
  • [Cites] Childs Nerv Syst. 1998 Dec;14(12):713-8 [9881624.001]
  • [Cites] Surg Neurol. 1989 Mar;31(3):234-8 [2922669.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1203-8 [8339211.001]
  • [Cites] Acta Neurol Belg. 1990;90(3):149-56 [2120904.001]
  • [Cites] J Pediatr Surg. 1995 Nov;30(11):1607-8 [8583337.001]
  • (PMID = 15719274.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 43
  •  go-up   go-down


13. Carter MR, Hornick JL, Lester S, Fletcher CD: Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol; 2006 Mar;30(3):300-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because the term "metaplastic carcinoma" comprises a heterogeneous group of tumors, it has been difficult to reliably predict biologic potential or to determine optimal therapy.
  • Treatment was by excision and/or mastectomy with axillary node evaluation in most cases, often combined with postoperative radiation and/or chemotherapy.
  • Two cases exhibited heterologous elements (1 rhabdomyosarcoma and 1 with both chondrosarcoma and osteosarcoma) and 4 were associated with ductal carcinoma in situ.
  • Of 20 cases in which axillary nodes were biopsied, definitive nodal metastases were identified in only 1 (5%), and this was in a case with a significant component of invasive ductal carcinoma.
  • Three patients developed local recurrences.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2007 Feb;31(2):326-7; author reply 327 [17255781.001]
  • (PMID = 16538049.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Wang JN, Yao CT, Chen JS, Yang YJ, Tsai YC, Wu JM: Cardiac tumors in infants and children. Acta Paediatr Taiwan; 2003 Jul-Aug;44(4):215-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Improvements in diagnostic techniques, such as those offered by echocardiography, have made early detection of cardiac masses possible, with or without the presence of clinical symptoms.
  • Four of the fifteen cases were secondary metastatic tumors [hepatoblastoma (n = 2), hepatoma (n = 1) and rhabdomyosarcoma (n = 1)].
  • All four of the patients with secondary cardiac tumors continued to receive chemotherapy, and only one of them subsequently experienced regression.
  • 4) there is a strong possibility of regression of the primary cardiac tumor, with surgery recommended only when cardiac symptoms are severe; and, 5) unless there is a significant obstruction of blood flow, chemotherapy is still the treatment of choice for secondary cardiac tumors.
  • [MeSH-minor] Carcinoma, Hepatocellular / secondary. Child. Child, Preschool. Female. Hepatoblastoma / secondary. Humans. Infant. Infant, Newborn. Liver Neoplasms / pathology. Male. Rhabdomyosarcoma / secondary. Tuberous Sclerosis / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674225.001).
  • [ISSN] 1608-8115
  • [Journal-full-title] Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi
  • [ISO-abbreviation] Acta Paediatr Taiwan
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


15. Soyer T, Karnak I, Ciftci AO, Senocak ME, Tanyel FC, Büyükpamukçu N: The results of surgical treatment of chest wall tumors in childhood. Pediatr Surg Int; 2006 Feb;22(2):135-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results of surgical treatment of chest wall tumors in childhood.
  • Chest wall tumors (CWT) are rarely seen in childhood and surgery constitutes a complementary part of the therapy.
  • They were Ewing's sarcoma (ES) (n = 4), primitive neuroectodermal tumor (PNET) (n = 3), Askin's tumor (n = 1), rhabdomyosarcoma (RMS) (n = 2), neuroblastoma (n = 2), osteochondroma (n = 1), aneurysmal bone cyst (n = 2) and hamartoma (n = 2).
  • Preoperative chemotherapy was given to most patients with malignant tumor.
  • All patients had only local tumor at the time of resection.
  • All tumor tissues with the affected rib/ribs were resected en bloc with the adjacent tissues.
  • All patients with malignant tumor received postoperative chemotherapy.
  • Five patients developed distant metastasis and two died.
  • Since most of the CWT are malignant and not initially suitable for surgical excision, the management includes tissue diagnosis either by tru-cut or open biopsy.
  • Determination of malignant condition should be followed by an intensive chemotherapy.
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Male. Neoadjuvant Therapy. Reconstructive Surgical Procedures. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Pediatr Surg. 1994 Nov;3(4):267-76 [7850367.001]
  • [Cites] Spine (Phila Pa 1976). 1985 Sep;10 (7):618-22 [4071270.001]
  • [Cites] J Pediatr Surg. 1977 Dec;12(6):991-9 [201742.001]
  • [Cites] J Pediatr Surg. 1980 Dec;15(6):906-12 [7463293.001]
  • [Cites] Plast Reconstr Surg. 1996 Oct;98(5):804-10 [8823018.001]
  • [Cites] J Pediatr Surg. 1999 Dec;34(12):1773-8 [10626852.001]
  • [Cites] Ann Thorac Surg. 1988 Jul;46(1):40-4 [3382285.001]
  • [Cites] J Pediatr Surg. 1988 Jul;23(7):667-73 [3204468.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jun;119(6):1154-61 [10838532.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Mar;117(3):588-91; discussion 591-2 [10047664.001]
  • [Cites] J Spinal Disord. 1994 Dec;7(6):522-7 [7873852.001]
  • [Cites] J Pediatr Surg. 1978 Jun;13(3):275-80 [209164.001]
  • [Cites] J Pediatr Surg. 1994 Sep;29(9):1189-91 [7807342.001]
  • (PMID = 16328338.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


16. Wang KF, Wu B, Zhang Y: [Adult prostate sarcoma: a report of 6 cases with clinical analysis]. Zhonghua Nan Ke Xue; 2007 Jul;13(7):617-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the diagnosis, treatment and prognosis of sarcoma of the adult prostate.
  • METHODS: We reported 6 cases of sarcoma of the adult prostate, of which 3 were leiomyosarcoma, 2 rhabdomyosarcoma and 1 malignant neurilemoma, 2 at Ghavimi Stage II, 3 at Stage III and 1 at Stage IV.
  • Five of them received operation, radiotherapy and / or chemotherapy and 1 underwent cystostomy only.
  • RESULTS: Immunohistochemical dyeing showed vimentin to be positive while PSA and PAP negative in all the 6 cases, actin (HHF35) positive in the cases of leiomyosarcoma and rhabdomyosarcoma, and S-100 and lysozyme positive in the case of malignant neurilemoma.
  • [MeSH-major] Prostatic Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Actins / analysis. Adolescent. Adult. Combined Modality Therapy. Cystostomy. Drug Therapy. Fatal Outcome. Humans. Immunohistochemistry. Male. Neoplasm Staging. Prognosis. Radiotherapy. S100 Proteins / analysis. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725305.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / S100 Proteins; 0 / Vimentin
  •  go-up   go-down


17. Méndez R, Arnáiz S, Montero M, Tellado M, País E, Ríos J, Vela D: [Clinical patterns of soft-tissue sarcoma in children]. Cir Pediatr; 2001 Jan;14(1):14-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical patterns of soft-tissue sarcoma in children].
  • INTRODUCTION AND OBJECTIVES: Soft tissue sarcomas are rare mesenchymal neoplasms that constitute less than 10% of all pediatric malignancies.
  • The purpose of this work is to evaluate our clinical experience with soft tissue sarcomas in uncommon sites over the past 10 years in order to delimitate the prognostic factors in survival and modalities of treatment.
  • MATERIAL AND METHODS: Between 1989 and 1998, 10 patients were diagnosed with soft tissue sarcomas in uncommon sites and treated by us over a total number of 139 pediatric neoplasms (7.19%).
  • Variables investigated included histologic findings, tumor size, age at presentation, primary site, clinical group, radiologic test performed, surgical treatment, radiotherapy and adjuvant chemotherapy, complications and survival rates.
  • RESULTS: The following histologic types of these 10 tumors were identified: 1 hemangiopericytoma in oral cavity, 2 extraosseous Ewing's sarcoma, 1 botryoid rhabdomyosarcoma of the bladder, 1 mediastinal fibrosarcoma, 1 retroperitoneal rhabdomyosarcoma, 1 paratesticular rhabdomyosarcoma, 1 cervical condrosarcoma, 1 alveolar rhabdomyosarcoma and 1 deltoid rhabdomyosarcoma.
  • The mean age at diagnosis was 7 years (4.6 years accounted for rhabdomyosarcoma alone).
  • Adjuvant chemotherapy with IVA was followed by radiotherapy only in four patients.
  • All the children classified in clinical groups II, III or IV needed 2nd. line regimens of chemotherapy.
  • Three patients died in the follow-up instead of the multimodal treatment.
  • 2) radiotherapy will only be necessary if margins of resection cannot control the local disease, and 3) chemotherapy have not clearly demonstrated his benefits as adjuvant therapy in clinical group I lesions but his employ is recommended in all cases because of the poor prognosis due to local recurrence.
  • [MeSH-major] Sarcoma / therapy. Soft Tissue Neoplasms / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11339112.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down






Advertisement